Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses

Journal of Immunotherapy

Volumn 27, Issue 3, 2004, Pages 191-200

  Schumacher, Lana ^a   Ribas, Antoni ^a   Dissette, Vivian B ^a   McBride, William H ^a   Mukherji, Bijay ^b   Economou, James S ^a   Butterfield, Lisa H ^a,c  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Antigen presenting cells; Cytotoxic T lymphocytes; Dendretic cells; MART 1 Melan A; Tumor antigens

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 4344624918     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200405000-00003     Document Type: Article

References (67)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
2. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166: 4254-4259.
3. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
4. Banchereau J, Palucka K, Dhodpkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451-6458.
5. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2002.
6. Thurner B, Haendle I, Roder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
7. Lapointe R, Royal RE, Reeves ME, et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol. 2001;167:4758-4764.
8. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998;161:5607-5613.
9. Butterfield LH, Meng WS, Koh A, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001;166:5300-5308.
10. Arthur JF, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 1997;4:17-25.
11. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood. 1998;91:392-398.
12. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther. 2000;11:797-806.
13. Ribas A, Butterfield LH, Glaspy JA, et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;(in press)
14. Ribas A, Butterfield LH, Glaspy JA, et al. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002;2:57-78.
15. Engelmayer J, Larsson M, Subklewe M, et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol. 1999;163:6762-6768.
16. Pollara G, Speidel K, Samady L, et al. Herpes simplex virus infection of dendritic cells: balance among activation, inhibition, and immunity. J Infect Dis. 2003;187:165-178.
17. Salio M, Cella M, Suter M, et al. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol. 1999;29:3245-3253.
18. Kruse M, Rosorius O, Kratzer F, et al. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol. 2000;74:7127-7136.
19. Ardeshna KM, Pizzey AR, Thomas NS, et al. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br J Haematol. 2000;108:817-824.
20. Oh S, Eichelberger MC. Polarization of allogeneic T-cell responses by influenza virus-infected dendritic cells. J Virol. 2000;74:7738-7744.
21. Liu Y, Santin AD, Mane M, et al. Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J Interferon Cytokine Res. 2000; 20:21-30.
22. Ponnazhagan S, Mahendra G, Curiel DT, et al. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol. 2001;75:9493-9501.
23. Rouas R, Uch R, Cleuter Y, et al. Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints. Cancer Gene Ther. 2002;9:715-724.
24. Di Nicola M, Anichini A, Mortarini R, et al. Human dendritic cells: natural adjuvants in antitumor immunotherapy. Cytokines Cell Mol Ther. 1998;4:265-273.
25. Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol. 1999;73:10416-10425.
26. Roth MD, Cheng Q, Harui A, et al. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J Immunol. 2002;169:4651-4656.
27. Zhong L, Granelli-Piperno A, Choi Y, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol. 1999;29:964-972.
28. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol. 1999;162:6378-6383.
29. Linette GP, Shankara S, Longerich S, et al. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma. J Immunol. 2000;164:3402-3412.
30. Yoshimura S, Bondeson J, Foxwell BM, et al. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol. 2001;13: 675-683.
31. Diao J, Smythe JA, Smyth C, et al. Human PBMC-derived dendritic cells transduced with an adenovirus vectorinduce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther. 1999;6: 845-853.
32. Rea D, Schagen FH, Hoeben RC, et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol. 1999;73:10245-10253.
33. Nishimura N, Nishioka Y, Shinohara T, et al. Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells. Hum Gene Ther. 2001;12:333-346.
34. Rouard H, Leon A, Klonjkowski B, et al. Adenoviral transduction of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J Immunol Methods. 2000;241:69-81.
35. Jonuleit H, Tüting T, Steitz J, et al. Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther. 2000;7:249-254.
36. Perez-Diez A, Butterfield LH, Li L, et al. Generation of CD8+ and CD4+ T cell responses to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res. 1998;58:5305-5309.
37. Butterfield LH, Koh A, Meng W, et al. Generation of human T-cell responses to an HLA-A2. 1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999;59:3134-3142.
38. Meng WS, Butterfield LH, Ribas A, et al. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol. 2000;37:943-950.
39. Meng WS, Butterfield LH, Ribas A, et al. Alpha-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 2001;61:8782-8786.
40. Vollmer CM Jr, Eilber FC, Butterfield LH, et al. Alpha-fetoprotein- specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 1999;59:3064-3067.
41. Butterfield LH, Stoll TC, Lau R, et al. Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. Gene. 1997;191: 129-134.
42. Toloza EM, Hunt K, Swisher S, et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther. 1996;3: 11-17.
43. Plebanski M, Allsopp CE, Aidoo M, et al. Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur J Immunol. 1995;25:1783-1787.
44. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
45. Herr W, Schneider J, Lohse AW, et al. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods. 1996;191:131-142.
46. Mayer S, Scheibenbogen C, Lee KH, et al. A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J Immunol Methods. 1996;197:131-137.
47. Corinti S, Albanesi C, la Sala A, et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol. 2001;166:4312-4318.
48. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755-1766.
49. De Smedt T, Van Mechelen M, De Becker G, et al. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol. 1997;27: 1229-1235.
50. Brossart P, Zobywalski A, Grunebach F, et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 2000;60:4485-4492.
51. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Adv Exp Med Biol. 1997;417:323-327.
52. Lundqvist A, Choudhury A, Nagata T, et al. Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther. 2002;13:1541-1549.
53. Morelli AE, Larregina AT, Ganster RW, et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol. 2000;74:9617-9628.
54. Lyakh LA, Koski GK, Young HA, et al. Adenovirus type 5 vectors induce dendritic cell differentiation in human CD 14(+) monocytes cultured under serum-free conditions. Blood. 2002;99:600-608.
55. Caux C. Pathways of development of human dendritic cells. Eur J Dermatol. 1998;8:375-384.
56. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999;283:1183-1186.
57. Corinti S, Medaglini D, Cavani A, et al. Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4+ T lymphocytes. J Immunol. 1999; 163:3029-3036.
58. Kiertscher SM, Roth MD. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996;59:208-218.
59. Kiertscher SM, Luo J, Dubinett SM, et al. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000;164:1269-1276.
60. Hertz CJ, Kiertscher SM, Godowski PJ, et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol. 2001;166:2444-2450.
61. Mazzoni A, Young HA, Spitzer JH, et al. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest. 2001;108:1865-1873.
62. de Saint-Vis B, Fugier-Vivier I, Massacrier C, et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol. 1998;160:1666-1676.
63. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003;9:998-1008.
64. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61: 8513-8519.
65. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
66. Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 1998;36:39-44.
67. Chakraborty A, Li L, Chakraborty NG, et al. Stimulatory and inhibitory differentiation of human myeloid dendritic cells. Clin Immunol. 2000;94: 88-98.